Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
    • Funding Acknowledgements
    • Network Sites
    • Staff Spotlight
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
  • News & Events
    • Conferences & Other Meetings
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Emily A. Barr

Email

emily.barr@childrenscolorado.org

Phone

720-777-6752

Institution

University of Colorado Children’s Hospital

Role

Study Coordinator

Address

University of Colorado Denver
Department of Pediatrics
13123 E. 16th Avenue B-055
Aurora, CO 80045

Request an Update

Affiliated Studies

P1026S: PK in Pregnancy

DAIDS Number

10040

Research Area

Treatment

Study Status

Closed to Follow Up

Locality

US & Non-US

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Complications & Comorbidities

Study Status

Enrolling

Locality

United States

P1041: Efficacy of Isoniazid to prevent TB

DAIDS Number

10047

Research Area

Other

Study Status

Participants Off Study and Primary Analysis Completed

Locality

Non-US

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Treatment

Study Status

Pending

Locality

US & Non-US

P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT

DAIDS Number

10166

Research Area

Treatment

Study Status

Concluded

Locality

Non-US
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network